Prospective Evaluation of Radiotherapy-Induced Immunologic and Genetic Effects in Colorectal Cancer Oligo-Metastatic Patients with Lung-Limited Disease: The PRELUDE-1 Study

• Published in: Cancers Vol. 13; no. 16; p. 4236
• Main Authors: Ottaiano, Alessandro, Petito, Angela, Santorsola, Mariachiara, Gigantino, Valerio, Capuozzo, Maurizio, Fontanella, Daniela, Di Franco, Rossella, Borzillo, Valentina, Buonopane, Sergio, Ravo, Vincenzo, Scipilliti, Esmeralda, Totaro, Giuseppe, Serra, Marcello, Ametrano, Gianluca, Penta, Roberta, Tatangelo, Fabiana, Scognamiglio, Giosuè, Di Mauro, Annabella, Di Bonito, Maurizio, Napolitano, Maria, Scala, Stefania, Rea, Giuseppina, Santagata, Sara, Lombardi, Angela, Grimaldi, Anna, Caputo, Carlo, Crispo, Anna, Celentano, Egidio, De Feo, Gianfranco, Circelli, Luisa, Savarese, Giovanni, Ruggiero, Raffaella, Perri, Francesco, Granata, Vincenza, Botti, Gerardo, Caraglia, Michele, Nasti, Guglielmo, Muto, Paolo
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23.08.2021; MDPI
• Subjects: Antigens; Biopsy; Cancer therapies; Cloning; Colorectal cancer; Colorectal carcinoma; Cytokines; Drug dosages; Evolution; Evolution & development; Genomes; Haplotypes; Histocompatibility antigen HLA; Hypotheses; Kinases; Lung cancer; Lung diseases; Lymphocytes; Medical prognosis; Metastases; Metastasis; Mutation; Next-generation sequencing; Peptides; Radiation therapy; Study Protocol; Toxicity; Translation; Tumor necrosis factor-TNF; Tumors; stereotactic radiation therapy; KRAS; colorectal cancer; abscopal effect; lung metastases
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13164236

in recent years, the management of advanced colorectal cancer (CRC) has been greatly improved with integrated strategies including stereotactic radiation therapy (SRT). The administration of SRT has been demonstrated, particularly in oligo-metastatic (om) CRC, to be a safe and effective option. Interestingly, it has been demonstrated that SRT can induce regression of tumors in non-irradiated regions ("abscopal effect") through stimulation of anti-tumor immune effects ("radiation-induced immunity"). We have recently shown that lung-limited omCRC is characterized by regression of tumor clones bearing specific key driver gene mutations. to assess the genetic evolution on tumor cancer cells induced by SRT in lung-limited omCRC. Secondary objectives included descriptions of the abscopal effect, responses' duration, toxicity, and progression-free survival. A translational research will be performed to evaluate tumor genetic evolution (through liquid biopsies and Next Generation Sequencing), HLA class I repertoire, peripheral immune cells, and cytokine dynamics. PRELUDE-1 is a prospective translational study. SRT will be administered only to the largest nodule (with a maximum diameter ≤ 25 mm) in omCRC with two or three radiologically evident lesions. The sample size is based on the innovative hypothesis that radiation-induced immunity could induce regression of tumor clones bearing KRAS oncogene mutations. According to the binomial test, considering the frequency of KRAS mutations and assuming a probability of mutant KRAS→wild type KRAS of p = 0.0077, with α = 0.05 and 1-β = 0.60, the final sample size is 25 patients.